OXY-TREAT

OXY-TREAT is a Swiss dermo-cosmetic skincare line built around oxygen-delivery technology. It is a sub-brand of Labo Cosprophar AG, the Basel company that trades as Labo Suisse and also owns Fillerina and Crescina [1]. The range centres on "in-depth oxygen treatments inspired by regenerative medicine," combining what the company calls Active Oxygen with molecules designed to penetrate the skin, and is sold chiefly through pharmacies as an at-home alternative to aesthetic-medicine procedures.

The brand remains active as part of a working parent portfolio, though its own public profile is quiet: the most recent OXY-TREAT-specific content traced online is a 2022 video, while Labo Suisse's shared social channels stay current [14]. The line spans 33 formulations across face and body concerns, and its full product catalogue is listed and priced on the official site.

⚑ Thinner sourcing. The article relies largely on the brand's own statements (T2–T3). Glowpedia is seeking independent sources.

OXY-TREAT sits inside Labo Suisse, the trading name of Labo Cosprophar AG. The parent describes itself as founded in Basel, Switzerland, in 1986, and positions itself as a "market leader in premium dermo-cosmetic products inspired by aesthetic medicine" [2]. Sources give different founding years depending on which legal entity is measured: the Swiss parent's own corporate page states 1986 [2], while the group's LinkedIn profile lists 1996 — a date that refers to the Italian subsidiary, Labo International [11]. The Italian entity, Labo International S.R.L., was separately registered in 2012 according to the Italian Trade Agency [10]. Because the Swiss parent holds the OXY-TREAT trademark and its patents, the 1986 Basel date is the brand-relevant origin.

The company operates as a Swiss firm with an Italian branch, with manufacturing tied to both Switzerland and Italy. Alongside OXY-TREAT, the group's portfolio includes Fillerina, a hyaluronic-acid "filler effect" line, and Crescina, a hair-growth treatment, among others [1]. According to the Italian Trade Agency listing, the company reported annual turnover above €25 million for 2021, employs roughly 50 to 99 people, and retails in more than 40 markets [10].

OXY-TREAT is presented as a professional-grade, at-home skincare system rather than a mass-market cosmetic line. Labo describes its wider mission as seeking "cosmetic solutions that rival aesthetic medicine's performance while offering non-invasive alternatives," and OXY-TREAT applies that idea specifically to oxygenation. The brand's rationale rests on a physiological claim: that oxygen concentration in the skin declines with age, which it links to premature ageing, wrinkles and discoloration, and that restoring deep oxygenation offers detoxifying, brightening and soothing benefits.

The company frames the range around four stated corporate values — Excellence, Innovation, Taking Care, and Added Value [2]. Distribution follows a pharmacy model: the group markets itself as a maker of "Special Cosmetics for Pharmacies" sold through a network of exclusive distributors, which it describes as spanning more than 40 countries [11].

The OXY-TREAT catalogue covers 33 formulations, split by the brand into 21 face products — targeting wrinkles, anti-ageing, firmness, dry or sensitive skin, clarifying, dark spots and oily skin — and 12 body products, chiefly cellulite and slimming treatments. Signature items include the Anti-Age Intensive Treatment, a 14-dose evening course, and the Anti-Age Day Cream positioned as maintenance after that cycle, along with Clarifying, Wrinkles and Cellulite treatments.

At the centre of the line is what the company calls its Active Oxygen and Transdermic technology. The system uses carbon-fluorine compounds known as perfluorocarbons — specifically perfluorohexane, perfluorodecalin and perfluoromethylcyclopentane — as carriers that, in the brand's description, load with oxygen and deliver it deep into the skin alongside functional molecules such as carnosine, ubiquinone, melatonin and teprenone. Labo says this Transdermic approach has been applied across all its products since 2015 [3]. The OXY-TREAT line is specifically protected under Swiss patent CH 719 330, described as a "dermocosmetic composition containing oxygen transported by an artificial oxygen carrier," part of a wider group portfolio the company states runs to 30 Swiss patents and 64 registered trademarks [4].

The brand's efficacy figures are drawn from its own research and stated as such. In vitro testing reported by the company showed intracellular oxygen rising by about 160% under standard conditions after 30 minutes and 140% under low-oxygen conditions after 60 minutes [1]. Labo also reports penetration rates for individual actives — for example around 89.9% for hydrolyzed Myrtus communis extract — and says its Transdermic research program has tested 216 active molecules across 297 studies in total [3]. These results are brand-reported and not independently verified.

OXY-TREAT is classified as active. Its parent, Labo Cosprophar AG, holds an extensive patent and trademark portfolio, maintains a current brand page for the line, and keeps the full 33-product OXY-TREAT catalogue listed and priced on labosuisse.com. The parent's own social channels remain active, including an Instagram account reported to have around 38,000 followers. The most recent OXY-TREAT-specific public content identifiable is a YouTube video about the Cellulite treatment posted in April 2022 [14]; more recent activity centres on the parent brand rather than OXY-TREAT by name.